Showing 1,021 - 1,040 results of 140,546 for search '(( 50 ((ns decrease) OR (a decrease)) ) OR ( 10 ((mean decrease) OR (we decrease)) ))', query time: 1.30s Refine Results
  1. 1021

    Image_1_EEG 40 Hz Coherence Decreases in REM Sleep and Ketamine Model of Psychosis.TIF by Santiago Castro-Zaballa (6238823)

    Published 2019
    “…On the contrary, gamma power was relatively high under ketamine, and similar to QW and REM sleep. We conclude that functional interactions between cortical areas in the gamma frequency band decrease in both experimental models of psychosis. …”
  2. 1022

    Time-course of changes induced on NCAM and SYN synaptic patterns and levels by glutamate exposure. by María Fernanda Podestá (639243)

    Published 2014
    “…Scale bars: 50 µm and 10 µm as magnification increases. NCAM: neural cell adhesion molecule; SYN: synaptophysin.…”
  3. 1023

    Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study by Jon Jarløv Rasmussen (2993427)

    Published 2016
    “…All participants were aged 18–50 years and were involved in recreational strength training. …”
  4. 1024

    DataSheet_1_A History of Endometriosis Is Associated With Decreased Peripheral NK Cytotoxicity and Increased Infiltration of Uterine CD68+ Macrophages.docx by Linlin Wang (289071)

    Published 2021
    “…Peripheral NK cytotoxicity at effector-to-target ratios of 25:1 and 50:1 was significantly reduced in women with a history of endometriosis from that of the control group (26.6% versus 33.3% and 36.1% versus 43.3%, respectively, both P < 0.001). …”
  5. 1025

    DataSheet_1_A History of Endometriosis Is Associated With Decreased Peripheral NK Cytotoxicity and Increased Infiltration of Uterine CD68+ Macrophages.docx by Linlin Wang (289071)

    Published 2023
    “…Peripheral NK cytotoxicity at effector-to-target ratios of 25:1 and 50:1 was significantly reduced in women with a history of endometriosis from that of the control group (26.6% versus 33.3% and 36.1% versus 43.3%, respectively, both P < 0.001). …”
  6. 1026
  7. 1027

    DataSheet_1_Accelerating Decreases in the Incidences of Hepatocellular Carcinoma at a Younger Age in Shanghai Are Associated With Hepatitis B Virus Vaccination.docx by Shunzhang Yu (12340927)

    Published 2022
    “…HCC incidences in males at younger age groups (age <50 years old), particularly in those with age <34 groups, showed an accelerating decrease over time, whereas HCC incidences significantly declined in the female population across all age groups except for those under 19 years of age. …”
  8. 1028

    DataSheet_1_Accelerating Decreases in the Incidences of Hepatocellular Carcinoma at a Younger Age in Shanghai Are Associated With Hepatitis B Virus Vaccination.docx by Shunzhang Yu (12340927)

    Published 2022
    “…HCC incidences in males at younger age groups (age <50 years old), particularly in those with age <34 groups, showed an accelerating decrease over time, whereas HCC incidences significantly declined in the female population across all age groups except for those under 19 years of age. …”
  9. 1029
  10. 1030
  11. 1031

    DAF-16/FOXO is Required for Locomotory Healthspan and Lifespan Benefits of Genetic Glycolysis Disruption. by Brian Onken (86790)

    Published 2020
    “…<i>daf-16</i> mutants are documented to have lowered locomotory ability vs. WT later in life [<a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008982#pgen.1008982.ref091" target="_blank">91</a>, <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008982#pgen.1008982.ref092" target="_blank">92</a>]; we note that, although comparison of scores across experiments is not possible due to variation in baseline values, the swimming rate of <i>daf-16(mgDf50)</i> control animals was slightly lower than WT controls on the same day of life (in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008982#pgen.1008982.g001" target="_blank">Fig 1C</a>; mean of 46.17 head thrashes/30 sec. for <i>daf-16</i> vs. 52.17 head thrashes/30 sec. for WT on day 10). …”
  12. 1032

    Glutamate exposure reduces MAP-2 immunostaining and induces changes in synaptic markers and cell adhesion molecule NCAM in the absence of neuronal death. by María Fernanda Podestá (639243)

    Published 2014
    “…PSA-NCAM immunoreactive area drastically decreased. Results are expressed as mean values (±SEM) of 20-30 neurons or 10 microscope fields (280,000 µm<sup>2</sup>/FOV) per experimental condition. …”
  13. 1033
  14. 1034
  15. 1035

    N2142A mutation reduced viral replication and binding to cell by impairing receptor binding. by Xue Li (285380)

    Published 2023
    “…<b>(C)</b> The fraction #10 samples of CVA10-WT and CVA10-N142A were diluted to 50 μg/ml and subjected to negative stain electron microscopy. …”
  16. 1036

    Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  17. 1037

    Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  18. 1038

    Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  19. 1039

    Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”
  20. 1040